Emerging research suggests GLP-1 receptor agonists like semaglutide and tirzepatide may reduce cravings for alcohol and other substances by modulating dopamine signaling in the brain’s reward circuitry — the same “food noise” mechanism that drives weight-loss outcomes. No GLP-1 is FDA-approved for any addiction indication. This guide explains what the human evidence actually shows, substance by substance, and how PlexusDx Weight Management Protocols are positioned for chronic weight management only.
How Does Genetics Affect Libido? What the Research Reveals
Libido has a genetic architecture — DRD2 receptor density, OXTR bonding sensitivity, MTNR1B circadian timing, and MC4R central arousal signaling all shape sexual desire at the neurochemical level. The Precision Peptide Genetic Test maps these variables as part of 14 pathways, 49 peptides, and 150+ genetic insights, explaining the biology of desire that testosterone panels miss.
DRD2 Dopamine Receptor and Desire Pathways: What Your Genes Reveal
DRD2 encodes the D2 dopamine receptor that governs the motivation, anticipation, and reward dimensions of sexual desire. The Precision Peptide Genetic Test analyzes DRD2 variants as part of 14 pathways, 49 peptides, and 150+ genetic insights — mapping the neurochemical foundation of sexual drive that no testosterone panel captures.